-$0.57 Earnings Per Share Expected for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) This Quarter

Equities research analysts expect Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to announce earnings per share (EPS) of ($0.57) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kiniksa Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.54). Kiniksa Pharmaceuticals reported earnings of ($0.88) per share during the same quarter last year, which indicates a positive year over year growth rate of 35.2%. The business is scheduled to issue its next earnings report on Thursday, March 5th.

According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($2.99) per share for the current fiscal year, with EPS estimates ranging from ($3.02) to ($2.96). For the next year, analysts expect that the company will post earnings of ($2.63) per share, with EPS estimates ranging from ($2.76) to ($2.50). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.23.

Several research firms have issued reports on KNSA. Zacks Investment Research raised Kiniksa Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $8.00 price target on the stock in a research note on Saturday, November 2nd. JMP Securities dropped their price target on Kiniksa Pharmaceuticals to $35.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 14th. They noted that the move was a valuation call. Wedbush reissued a “buy” rating on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, August 14th. Finally, Goldman Sachs Group raised Kiniksa Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $16.00 to $18.00 in a research note on Friday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Kiniksa Pharmaceuticals has an average rating of “Buy” and an average target price of $24.00.

Kiniksa Pharmaceuticals stock traded up $1.55 during mid-day trading on Thursday, hitting $12.92. 629,581 shares of the company’s stock were exchanged, compared to its average volume of 139,347. The firm has a market capitalization of $582.26 million, a P/E ratio of -3.70 and a beta of -1.02. Kiniksa Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $28.90. The company’s 50 day simple moving average is $8.09 and its 200-day simple moving average is $10.57.

Several institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Point72 Asset Management L.P. boosted its position in shares of Kiniksa Pharmaceuticals by 300.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 140,000 shares of the company’s stock valued at $1,191,000 after acquiring an additional 105,000 shares during the last quarter. State Street Corp increased its holdings in shares of Kiniksa Pharmaceuticals by 4.2% during the 3rd quarter. State Street Corp now owns 229,477 shares of the company’s stock valued at $1,953,000 after purchasing an additional 9,282 shares in the last quarter. First Manhattan Co. increased its holdings in shares of Kiniksa Pharmaceuticals by 68.3% during the 2nd quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock valued at $866,000 after purchasing an additional 25,970 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 195.8% during the 2nd quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock valued at $5,041,000 after purchasing an additional 246,442 shares in the last quarter. Finally, Morgan Stanley increased its holdings in shares of Kiniksa Pharmaceuticals by 54.2% during the 2nd quarter. Morgan Stanley now owns 60,098 shares of the company’s stock valued at $814,000 after purchasing an additional 21,130 shares in the last quarter. 29.85% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Featured Story: The basics of gap trading strategies

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.